Zhonghua nei ke za zhi
-
Zhonghua nei ke za zhi · Oct 2020
Multicenter Study[The prognostic role of the programmed death-1 expression on T lymphocytes in septic patients].
Objective: To investigate the value of programmed death-1（PD-1） expression on the T lymphocytes for the prognosis of septic patients. Methods: From September 2017 to May 2019, septic patients were included in Department of Intensive Care Unit at 6 hospitals. The PD-1 expression on T cells were measured by flow cytometry. ⋯ The percentage of PD-1+/CD8+T cell was 3.91%, with AUC 0.771, sensitivity 64.29%, specificity 81.25%，(P=0.000 3). Conclusions: The T cell PD-1 expression is an independent risk factor to predict the 28-day mortality in septic patients. Combining the proportions of PD-1+/CD3+, PD-1+/CD4+and PD-1+/CD8+T cells may further enhance the predictive value for death.
-
Zhonghua nei ke za zhi · Jul 2017
Multicenter Study Observational Study[A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Objective: To evaluate the efficacy and safety of lenalidomide in a real-world clinical practice in Chinese patients with multiple myeloma (MM). Methods: It was a prospective, multi-center, observational study. A total of 165 consecutive patients with MM treated with lenalidomide-based regimens were enrolled in 12 hospitals from June 2013 to November 2015. ⋯ The toxicity is quite tolerable and manageable. In addition, the response to previous treatment (reached PR or above) is the independent good prognostic factor for PFS, non-bortezomib resistance and non-primary refractoriness for OS. Clinical trail registration: Clinicaltrials.gov, NCT01947309.
-
Zhonghua nei ke za zhi · Dec 2014
Multicenter Study[The 10-year stroke risk in hypertensive outpatients combined with diabetes in cardiovascular clinics of 36 tertiary hospitals in China].
To assess the estimated 10-year risk of stroke among hypertensive outpatients known with diabetes from cardiovascular clinics of 36 tertiary hospitals in China and to analyze the characteristics of the risk factors and the 10-year risk of stroke between the southern and the northern patients. ⋯ Among the hypertensive outpatients known with diabetes from the cardiovascular clinics of our study, most of them were at the 10-year high risk of stroke. The southern patients had a higher mean 10-year probability of stroke than that of the northern patients.
-
Zhonghua nei ke za zhi · Apr 2013
Randomized Controlled Trial Multicenter Study[The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
To evaluate the efficacy and safety of human anti-interleukin-6 (IL-6) receptor antibody (tocilizumab) in combination with disease-modifying anti-rheumatoid drugs (DMARDs) for the treatment of rheumatoid arthritis (RA) patients with moderate to severe activity and inadequate response to DMARDs. ⋯ The study showed that tocilizumab combined with DMARDs was safe and effective in reducing articular and systemic symptoms in patients with an inadequate response to DMARDs.
-
Zhonghua nei ke za zhi · Dec 2001
Randomized Controlled Trial Multicenter Study[A multicenter study of efficacy and safety of oseltamivir in treatment of naturally acquired influenza].
To evaluate the efficacy and safety of oseltamivir in the treatment of naturally acquired influenza in China. ⋯ Oseltamivir was effective and well tolerated in the treatment of early naturally acquired influenza.